J&J's Quad HIV Combo Likely To Pass CHMP; EU Market Uptake Is Trickier

 
• By Lucie Ellis-Taitt

Johnson & Johnson's quadruple HIV combination is likely to win a positive recommendation for approval in Europe this week – but clever positioning will be required to secure strong uptake for the combination considering its late entry onto a competitive market place.

HIV virus
Janssen's Quad HIV Treatment Must Cleverly Compete With Marketed Options And Incoming Therapies

More from New Products

More from Scrip